Orphan
medications are drugs that are developed for the treatment of rare diseases and
situations. Tourette syndrome, Huntington's disease, muscular dystrophy,
myoclonus, and ALS (Lou Gehrig's disease) are examples of uncommon disorders
for which no appropriate medications have been produced, and thus these
diseases are treated using orphan drugs. Orphan medications are produced by
pharmaceutical corporations to meet a public health need, and their sales are
very low when compared to standard drugs. Patients with orphan diseases account
for 6-8 percent of the global population. Some orphan diseases, such as cystic
fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis
(FAP), and others, have symptoms that occur at birth or in childhood.
The orphan
drugs market into five regions: North America, Latin America, Europe,
Asia Pacific, the Middle East, and Africa. North America dominates the global
market due to factors such as a well-established regulatory and reimbursement
system, as well as incentives provided by the US Food and Drug Administration
(FDA) for orphan drug research and development. The orphan drug industry is
boosted by different joint research programmes across the United States and
Europe that deliver research data on rare diseases to producers, patients, and
health specialists, allowing for prompt medical care. The incidence of genetic
illnesses and population expansion are two variables that may encourage orphan
medicine companies to invest in the Asia Pacific area.
Impact of COVID-19 Pandemic on Orphan
Drugs Market
The COVID-19
pandemic has wreaked havoc on health-care workflows all around the world.
Various industries, including several sub-domains of healthcare, have been
forced to temporarily close their doors because to the sickness. A decline in
screening services, reduced access to specialists, treatment interruption,
limited operations in most industries, inadequate funding to research &
academic institutes, temporary closure of major academic institutes, and
disrupted supply chain and challenges in terms of providing
essential/post-sales services are all contributing to the orphan drug market's
negative growth. However, the market is expected to rebound in 2021, with
orphan medications continuing to rise at a steady rate.
Comments
Post a Comment